COVID-19 Emotional and Mental Impact on Cancer Patients Receiving Radiotherapy: An Interpretation of Potential Explaining Descriptors.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
01 01 2023
Historique:
received: 27 11 2022
revised: 24 12 2022
accepted: 29 12 2022
entrez: 20 1 2023
pubmed: 21 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

Background: Significant changes in the accessibility and viability of health services have been observed during the COVID-19 period, particularly in vulnerable groups such as cancer patients. In this study, we described the impact of radical practice and perceived changes on cancer patients’ mental well-being and investigated potential outcome descriptors. Methods: Generalized anxiety disorder assessment (GAD-7), patient health (PHQ-9), and World Health Organization-five well-being index (WHO-5) questionnaires were used to assess anxiety, depression, and mental well-being. Information on participants, disease baseline information, and COVID-19-related questions were collected, and related explanatory variables were included for statistical analysis. Results: The mean score values for anxiety, depression, and mental well-being were 4.7 ± 5.53, 4.9 ± 6.42, and 72.2 ± 18.53, respectively. GAD-7 and PHQ-9 scores were statistically associated (p < 0.001), while high values of GAD-7 and PHQ-9 questionnaires were related to low values of WHO-5 (p < 0.001).Using the GAD-7 scale, 16.2% of participants were classified as having mild anxiety (GAD-7 score: 5−9).Mild to more severe anxiety was significantly associated with a history of mental health conditions (p = 0.01, OR = 3.74, 95% CI [1.372−10.21]), and stage category (stage III/IV vs. I/II, p = 0.01, OR = 3.83, 95% CI [1.38−10.64]. From the participants, 36.2% were considered to have depression (PHQ-9 score ≥ 5). Depression was related with older patients (p = 0.05, OR = 1.63, 95% CI [1.16−2.3]), those with previous mental health conditions (p = 0.03, OR = 14.24, 95% CI [2.47−81.84]), those concerned about the COVID-19 impact on their cancer treatment (p = 0.027, OR = 0.19, 95% CI [0.045−0.82]) or those who felt that COVID-19 pandemic has affected mental health (p = 0.013, OR = 3.56, 95% CI [1.30−9.72]). Additionally, most participants (86.7%) had a good well-being score (WHO-5 score ≥ 50). Mental well-being seemed more reduced among stage I−III patients than stage IV patients (p = 0.014, OR = 0.12, 95% CI [0.023−0.65]). Conclusion: There is a necessity for comprehensive cancer care improvement. These patients’ main concern related to cancer therapy, yet the group of patients who were mentally affected by the pandemic should be identified and supported.

Identifiants

pubmed: 36661695
pii: curroncol30010046
doi: 10.3390/curroncol30010046
pmc: PMC9857784
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

586-597

Références

Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Prim Care Companion CNS Disord. 2022 Jul 19;24(4):
pubmed: 35878545
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Exp Ther Med. 2020 Nov;20(5):73
pubmed: 32968430
Int J Surg. 2020 Jun;78:185-193
pubmed: 32305533
JAMA Oncol. 2021 Feb 1;7(2):279-284
pubmed: 33237294
Rev Recent Clin Trials. 2022;17(1):11-14
pubmed: 34967300
J Cancer. 2020 Aug 27;11(21):6243-6247
pubmed: 33033507
Cad Saude Publica. 2020;36(7):e00177020
pubmed: 32725086
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Clin Colorectal Cancer. 2022 Jun;21(2):e117-e125
pubmed: 34953674
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
Anticancer Res. 2021 Apr;41(4):1971-1974
pubmed: 33813403
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
JCO Glob Oncol. 2022 Feb;8:e2100339
pubmed: 35213235
Transl Psychiatry. 2021 Aug 4;11(1):418
pubmed: 34349100
Soc Sci Med. 2021 Jan;268:113554
pubmed: 33308911
JAMA Intern Med. 2020 Jun 1;180(6):817-818
pubmed: 32275292
Oral Dis. 2022 Nov;28 Suppl 2:2391-2399
pubmed: 33853205
Int J Biol Markers. 2007 Jan-Mar;22(1):12-8
pubmed: 17393356
Med Health Care Philos. 2021 Dec;24(4):487-492
pubmed: 34398349
J Clin Oncol. 2021 Jul 10;39(20):2232-2246
pubmed: 34085538
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Breast Cancer. 2018 Jul;25(4):464-469
pubmed: 29442215
Psychother Psychosom. 2015;84(3):167-76
pubmed: 25831962
Lancet Oncol. 2020 Jun;21(6):759-760
pubmed: 32410877
J BUON. 2020 May-Jun;25(3):1277-1280
pubmed: 32862566
J Clin Oncol. 2020 Jul 1;38(19):2201-2205
pubmed: 32343643
Aging Male. 2020 Dec;23(5):1416-1424
pubmed: 32508193
BMC Cancer. 2021 Dec 31;21(1):1356
pubmed: 34972520
Transl Oncol. 2022 Aug;22:101457
pubmed: 35607456
Lancet. 2020 Feb 22;395(10224):e37-e38
pubmed: 32043982
Cancer. 2021 Jan 15;127(2):266-274
pubmed: 33112411
Int J Surg. 2020 Apr;76:71-76
pubmed: 32112977
Front Public Health. 2022 Feb 09;9:788598
pubmed: 35223757
PLoS One. 2016 Apr 15;11(4):e0153714
pubmed: 27082440
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
Eur J Cancer Care (Engl). 2005 Mar;14(1):7-15
pubmed: 15698382
J Gastrointest Cancer. 2021 Jun;52(2):407-413
pubmed: 33244705
Front Oncol. 2020 Nov 19;10:575148
pubmed: 33330049
Curr Treat Options Oncol. 2021 Aug 23;22(10):93
pubmed: 34424418
Eur Arch Psychiatry Clin Neurosci. 2020 Sep;270(6):785-786
pubmed: 32415510
Prim Health Care Res Dev. 2019 Jul 25;20:e113
pubmed: 31668150
Cureus. 2020 May 21;12(5):e8224
pubmed: 32582485
Asian Pac J Cancer Prev. 2022 Jul 01;23(7):2415-2420
pubmed: 35901349
Cyberpsychol Behav Soc Netw. 2020 Nov;23(11):782-788
pubmed: 32640852

Auteurs

Maria Tolia (M)

Department of Radiation Oncology, School of Medicine, University of Crete, 71300 Heraklion, Greece.

Emmanouil K Symvoulakis (EK)

Clinic of Social and Family Medicine, School of Medicine, University of Crete, 71300 Heraklion, Greece.

Emmanouil Matalliotakis (E)

Department of Radiation Oncology, School of Medicine, University of Crete, 71300 Heraklion, Greece.

Apostolos Kamekis (A)

School of Medicine, University of Crete, 71300 Heraklion, Greece.

Marios Adamou (M)

School of Human and Health Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.

Panteleimon Kountourakis (P)

Department of Medical Oncology, Mediterranean Hospital of Cyprus, 3117 Limassol, Cyprus.

Davide Mauri (D)

Medical Oncology, University of Ioannina, 45500 Ioannina, Greece.

Antonios Dakanalis (A)

Department of Medicine and Surgery, University of Milano Bicocca, Via Cadore 48, 20900 Monza, Italy.

Petros Alexidis (P)

Department of Radiation Oncology, Papageorgiou Hospital, 56429 Thessaloniki, Greece.

Antonios Varveris (A)

Department of Radiation Oncology, School of Medicine, University of Crete, 71300 Heraklion, Greece.

Chrysostomos Antoniadis (C)

Department of Radiation Oncology, School of Medicine, University of Crete, 71300 Heraklion, Greece.

Dimitris Matthaios (D)

Oncology Department, General Hospital of Rhodes, 85133 Rhodes, Greece.

Maria Paraskeva (M)

Oncology Department, General Hospital of Rhodes, 85133 Rhodes, Greece.

Constantinos Giaginis (C)

Department of Food Science and Nutrition, School of Environment, University of the Aegean, Myrina, 81400 Lemnos, Greece.

Konstantinos Kamposioras (K)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH